BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia
This first clinical evaluation of BCMA CAR-T cell therapy in four patients with refractory primary ITP demonstrated manageable safety, rapid and sustained platelet recovery, and durable drug-free complete remission lasting up to 15 months, supporting further evaluation in larger studies.
Authors
- H Li
- Jinhui Shu (ORCID: https://orcid.org/0000-0002-0052-4424)
- Heng Mei (ORCID: https://orcid.org/0000-0001-7941-2443)
- Mei‐Yan Xu (ORCID: https://orcid.org/0000-0002-4234-4296)
- Peiru Li
- James B. Bussel (ORCID: https://orcid.org/0000-0002-2884-9247)
- Yu Hu (ORCID: https://orcid.org/0000-0002-2815-4568)
- Lin Liu
- Wei Xie
Institutions
- Union Hospital (HK)
- Cornell University (US)
- Wuhan Union Hospital (CN)
- China Shenhua Energy (China) (CN)
- Institute of Hydrology of the Slovak Academy of Sciences (SK)
- Weill Cornell Medicine (US)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Blood
- Published
- 2026-07-24
- DOI
- https://doi.org/10.1182/blood.2026035047
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00